| Literature DB >> 25760337 |
Marco R Oggioni1, Joana Rosado Coelho, Leonardo Furi, Daniel R Knight, Carlo Viti, Graziella Orefici, Jose-Luis Martinez, Ana Teresa Freitas, Teresa M Coque, Ian Morrissey.
Abstract
There is a growing concern by regulatory authorities for the selection of antibiotic resistance caused by the use of biocidal products. We aimed to complete the detailed information on large surveys by investigating the relationship between biocide and antibiotic susceptibility profiles of a large number of Staphylococcus aureus isolates using four biocides and antibiotics commonly used in clinical practice. The minimal inhibitory concentration (MIC) for most clinically-relevant antibiotics was determined according to the standardized methodology for over 1600 clinical S. aureus isolates and compared to susceptibility profiles of benzalkonium chloride, chlorhexidine, triclosan, and sodium hypochlorite. The relationship between antibiotic and biocide susceptibility profiles was evaluated using non-linear correlations. The main outcome evidenced was an absence of any strong or moderate statistically significant correlation when susceptibilities of either triclosan or sodium hypochlorite were compared for any of the tested antibiotics. On the other hand, correlation coefficients for MICs of benzalkonium chloride and chlorhexidine were calculated above 0.4 for susceptibility to quinolones, beta-lactams, and also macrolides. Our data do not support any selective pressure for association between biocides and antibiotics resistance and furthermore do not allow for a defined risk evaluation for some of the compounds. Importantly, our data clearly indicate that there does not involve any risk of selection for antibiotic resistance for the compounds triclosan and sodium hypochlorite. These data hence infer that biocide selection for antibiotic resistance has had so far a less significant impact than feared.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25760337 PMCID: PMC4460275 DOI: 10.2174/1381612821666150310103238
Source DB: PubMed Journal: Curr Pharm Des ISSN: 1381-6128 Impact factor: 3.116
Correlation coefficient between antimicrobial susceptibility profiles of over 1600 clinical S. aureus isolates.
| CLX | BZC | SHC | TRI | CLX* | BZC* | SHC* | TRI* | P | AMC | CXM | CEC | CPD | SXT | CC | E | CLR | AZM | TEL | SYN | TEC | VA | CIP | LVX | GAT | MFX | TE | LZD | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLX | 1.00 | |||||||||||||||||||||||||||
| BZC | 0.53 | 1.00 | ||||||||||||||||||||||||||
| SHC | 0.01 | 0.05 | 1.00 | |||||||||||||||||||||||||
| TRI | 0.07 | 0.01 | 0.21 | 1.00 | ||||||||||||||||||||||||
| CLX* | 0.07 | 0.02 | 0.09 | 0.04 | 1.00 | |||||||||||||||||||||||
| BZC* | 0.04 | 0.02 | 0.17 | 0.03 | 0.38 | 1.00 | ||||||||||||||||||||||
| SHC* | 0.15 | 0.14 | 0.42 | 0.19 | 0.31 | 0.33 | 1.00 | |||||||||||||||||||||
| TRI* | 0.13 | 0.10 | 0.21 | 0.61 | 0.11 | 0.08 | 0.37 | 1.00 | ||||||||||||||||||||
| P | 0.15 | 0.19 | 0.07 | 0.01 | 0.03 | 0.02 | 0.05 | 0.03 | 1.00 | |||||||||||||||||||
| AMC | 0.25 | 0.32 | 0.06 | 0.04 | 0.06 | 0.03 | 0.03 | 0.05 | 0.75 | 1.00 | ||||||||||||||||||
| CXM | 0.30 | 0.40 | 0.04 | 0.09 | 0.00 | 0.03 | 0.13 | 0.13 | 0.38 | 0.66 | 1.00 | |||||||||||||||||
| CEC | 0.28 | 0.37 | 0.01 | 0.06 | 0.00 | 0.02 | 0.11 | 0.09 | 0.71 | 0.81 | 0.67 | 1.00 | ||||||||||||||||
| CPD | 0.34 | 0.44 | 0.01 | 0.06 | 0.02 | 0.01 | 0.08 | 0.10 | 0.41 | 0.67 | 0.78 | 0.70 | 1.00 | |||||||||||||||
| SXT | 0.07 | 0.12 | 0.06 | 0.00 | 0.06 | 0.06 | 0.06 | 0.01 | 0.12 | 0.21 | 0.22 | 0.22 | 0.23 | 1.00 | ||||||||||||||
| CC | 0.29 | 0.33 | 0.03 | 0.05 | 0.02 | 0.01 | 0.07 | 0.09 | 0.28 | 0.46 | 0.51 | 0.46 | 0.55 | 0.20 | 1.00 | |||||||||||||
| E | 0.27 | 0.33 | 0.02 | 0.02 | 0.01 | 0.03 | 0.06 | 0.04 | 0.25 | 0.47 | 0.48 | 0.45 | 0.49 | 0.20 | 0.54 | 1.00 | ||||||||||||
| CLR | 0.24 | 0.29 | 0.03 | 0.03 | 0.01 | 0.01 | 0.02 | 0.03 | 0.24 | 0.44 | 0.45 | 0.42 | 0.47 | 0.19 | 0.53 | 0.86 | 1.00 | |||||||||||
| AZM | 0.23 | 0.30 | 0.07 | 0.02 | 0.03 | 0.02 | 0.01 | 0.02 | 0.25 | 0.45 | 0.44 | 0.40 | 0.47 | 0.18 | 0.54 | 0.89 | 0.86 | 1.00 | ||||||||||
| TEL | 0.33 | 0.35 | 0.01 | 0.07 | 0.03 | 0.02 | 0.08 | 0.10 | 0.26 | 0.46 | 0.50 | 0.45 | 0.54 | 0.23 | 0.73 | 0.59 | 0.56 | 0.59 | 1.00 | |||||||||
| SYN | 0.11 | 0.10 | 0.03 | 0.00 | 0.03 | 0.01 | 0.02 | 0.04 | 0.11 | 0.22 | 0.26 | 0.23 | 0.25 | 0.16 | 0.22 | 0.22 | 0.21 | 0.22 | 0.23 | 1.00 | ||||||||
| TEC | 0.08 | 0.02 | 0.05 | 0.02 | 0.04 | 0.02 | 0.02 | 0.03 | 0.00 | 0.03 | 0.04 | 0.08 | 0.03 | 0.05 | 0.09 | 0.11 | 0.10 | 0.09 | 0.11 | 0.33 | 1.00 | |||||||
| VA | 0.37 | 0.46 | 0.01 | 0.02 | 0.04 | 0.05 | 0.10 | 0.10 | 0.28 | 0.48 | 0.60 | 0.52 | 0.62 | 0.25 | 0.50 | 0.51 | 0.48 | 0.48 | 0.54 | 0.18 | 0.01 | 1.00 | ||||||
| CIP | 0.40 | 0.49 | 0.01 | 0.05 | 0.02 | 0.06 | 0.10 | 0.11 | 0.35 | 0.62 | 0.70 | 0.63 | 0.73 | 0.28 | 0.60 | 0.60 | 0.56 | 0.56 | 0.63 | 0.20 | 0.03 | 0.82 | 1.00 | |||||
| LVX | 0.34 | 0.40 | 0.00 | 0.05 | 0.01 | 0.02 | 0.07 | 0.09 | 0.26 | 0.50 | 0.60 | 0.51 | 0.61 | 0.27 | 0.52 | 0.49 | 0.46 | 0.46 | 0.54 | 0.19 | 0.03 | 0.78 | 0.77 | 1.00 | ||||
| GAT | 0.33 | 0.41 | 0.01 | 0.02 | 0.02 | 0.01 | 0.05 | 0.08 | 0.26 | 0.48 | 0.58 | 0.50 | 0.59 | 0.25 | 0.51 | 0.51 | 0.48 | 0.49 | 0.53 | 0.21 | 0.04 | 0.83 | 0.78 | 0.79 | 1.00 | |||
| MFX | 0.13 | 0.15 | 0.02 | 0.02 | 0.02 | 0.04 | 0.05 | 0.05 | 0.14 | 0.23 | 0.27 | 0.28 | 0.28 | 0.26 | 0.29 | 0.26 | 0.25 | 0.24 | 0.25 | 0.22 | 0.17 | 0.23 | 0.25 | 0.28 | 0.26 | 1.00 | ||
| TE | 0.26 | 0.30 | 0.04 | 0.03 | 0.03 | 0.06 | 0.11 | 0.09 | 0.27 | 0.36 | 0.45 | 0.42 | 0.46 | 0.13 | 0.51 | 0.40 | 0.38 | 0.37 | 0.54 | 0.21 | 0.18 | 0.44 | 0.49 | 0.40 | 0.41 | 0.27 | 1.00 | |
| LZD | 0.08 | 0.13 | 0.09 | 0.02 | 0.07 | 0.10 | 0.09 | 0.03 | 0.06 | 0.13 | 0.14 | 0.10 | 0.13 | 0.16 | 0.04 | 0.12 | 0.08 | 0.08 | 0.11 | 0.06 | 0.01 | 0.08 | 0.12 | 0.20 | 0.09 | 0.09 | 0.12 | 1.00 |
marks MBC. All shaded cells report statistically significant correlations. Amoxicillin with Clavulanic Acid AMC, Azithromycin AZM, Cefaclor CEC, Cefpodoxime CPD, Cefuroxime CXM, Ciprofloxacin CIP, Clarithromycin CLR, Clindamycin CC, Erythromycin E, Gatifloxacin GAT, Levofloxacin LVX, Linezolid LZD, Meticillin OXA, Moxifloxacin MFX, Penicillin P, Quinupristin/Dalfopristin SYN, Sulfamethoxazole with Trimethoprim SXT , Teicoplanin TEC, Telithromycin TEL, Tetracycline TE, Vancomycin VA.